Lisanti Capital Growth’s Ultragenyx Pharmaceutical RARE Stock Holding History

Lisanti Capital Growth’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-4,605	Closed	-$292K	–	115
2016 Q1	$292K	Buy	4,605 +220	+5%	+$14.4K	0.35%	94
2015 Q4	$492K	Buy	+4,385	New	+$438K	0.52%	79
2014 Q4	–	Sell	-25,170	Closed	-$1.43M	–	104
2014 Q3	$1.43M	Buy	+25,170	New	+$1.27M	0.72%	66
2014 Q2	–	Sell	-14,595	Closed	-$714K	–	109
2014 Q1	$714K	Buy	+14,595	New	+$751K	0.31%	88

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Lisanti Capital Growth's RARE Position: Q2 2016 in Review

Lisanti Capital Growth sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2016, closing a stake of 4,605 shares — an estimated $292K sold.

Lisanti Capital Growth first reported a position in RARE in Q1 2014 and held it in 4 quarters. The position peaked at $1.43M in Q3 2014. 161 funds tracked by Wall St. Rank hold RARE as of Q2 2016.

Lisanti Capital Growth reported no remaining Ultragenyx Pharmaceutical position as of Q2 2016 after selling out during the quarter.
Lisanti Capital Growth sold 4,605 Ultragenyx Pharmaceutical shares in Q2 2016, an estimated $292K.
Lisanti Capital Growth first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 4 quarters.
Lisanti Capital Growth's Ultragenyx Pharmaceutical position peaked at $1.43M in Q3 2014.
161 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2016.

Based on Lisanti Capital Growth's 13F filing for Q2 2016, filed 5 Aug 2016.